Cystatin C as an adjunct to HbA1c may prove useful in predicting the development of diabetic complications in children and adolescents with type 1 diabetes
(2024) In Journal of Diabetes and Metabolic Disorders 23(1). p.1251-1257- Abstract
Purpose: Complications from diabetes mellitus can occur over time and although glycosylated hemoglobin (HbA1c) is a good biomarker for glycaemic control, other factors also contribute to the development of complications in type 1 diabetes. More markers able to identify the risk of complications are needed. This study aimed to investigate plasma levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 in children and adolescents with different duration of type 1 diabetes and possible correlation to HbA1c to identify potential biomarkers of future complication development. Methods: Patients (n = 244, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital, Sweden, were included in this study. Circulating levels of FGF21, Cystatin C,... (More)
Purpose: Complications from diabetes mellitus can occur over time and although glycosylated hemoglobin (HbA1c) is a good biomarker for glycaemic control, other factors also contribute to the development of complications in type 1 diabetes. More markers able to identify the risk of complications are needed. This study aimed to investigate plasma levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 in children and adolescents with different duration of type 1 diabetes and possible correlation to HbA1c to identify potential biomarkers of future complication development. Methods: Patients (n = 244, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital, Sweden, were included in this study. Circulating levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 were investigated in plasma using automated ELISA with the ELLA™ system and standardised controls. Results: Cystatin C levels were elevated in patients with diabetes duration longer than 5 years (P < 0.001). HbA1c and Cystatin C levels were inversely correlated for all participants (rs = − 0.23, CI95: −0.35-−0.10; P < 0.001). A stepwise multiple regression analysis showed that HbA1c (P < 0.001) and Cystatin C (P = 0.03) were associated to the duration of diabetes at sampling while MMP-9, lipocalin-2, and FGF21 did not reach statistical significance. Conclusion: In conclusion, Cystatin C levels were higher in patients with diabetes duration longer than 5 years, and inverse correlation was found between HbA1c and Cystatin C levels as well as duration of diabetes. Cystatin C may prove useful as an adjunct to HbA1c in predicting eventual development of diabetic complications.
(Less)
- author
- Nilsson, Charlotta
LU
and Dereke, Jonatan
LU
- organization
- publishing date
- 2024-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Complications, HbA1c, Proteins, Type 1 diabetes
- in
- Journal of Diabetes and Metabolic Disorders
- volume
- 23
- issue
- 1
- pages
- 7 pages
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:38932813
- scopus:85190671150
- ISSN
- 2251-6581
- DOI
- 10.1007/s40200-024-01419-1
- language
- English
- LU publication?
- yes
- id
- 3a48704e-2d8b-4d90-b0e1-37f4d3ac351c
- date added to LUP
- 2025-01-15 10:21:10
- date last changed
- 2025-07-17 01:21:22
@article{3a48704e-2d8b-4d90-b0e1-37f4d3ac351c, abstract = {{<p>Purpose: Complications from diabetes mellitus can occur over time and although glycosylated hemoglobin (HbA1c) is a good biomarker for glycaemic control, other factors also contribute to the development of complications in type 1 diabetes. More markers able to identify the risk of complications are needed. This study aimed to investigate plasma levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 in children and adolescents with different duration of type 1 diabetes and possible correlation to HbA1c to identify potential biomarkers of future complication development. Methods: Patients (n = 244, 0–18 years) with type 1 diabetes, at Helsingborg’s Hospital, Sweden, were included in this study. Circulating levels of FGF21, Cystatin C, lipocalin-2, and MMP-9 were investigated in plasma using automated ELISA with the ELLA™ system and standardised controls. Results: Cystatin C levels were elevated in patients with diabetes duration longer than 5 years (P < 0.001). HbA1c and Cystatin C levels were inversely correlated for all participants (rs = − 0.23, CI95: −0.35-−0.10; P < 0.001). A stepwise multiple regression analysis showed that HbA1c (P < 0.001) and Cystatin C (P = 0.03) were associated to the duration of diabetes at sampling while MMP-9, lipocalin-2, and FGF21 did not reach statistical significance. Conclusion: In conclusion, Cystatin C levels were higher in patients with diabetes duration longer than 5 years, and inverse correlation was found between HbA1c and Cystatin C levels as well as duration of diabetes. Cystatin C may prove useful as an adjunct to HbA1c in predicting eventual development of diabetic complications.</p>}}, author = {{Nilsson, Charlotta and Dereke, Jonatan}}, issn = {{2251-6581}}, keywords = {{Complications; HbA1c; Proteins; Type 1 diabetes}}, language = {{eng}}, number = {{1}}, pages = {{1251--1257}}, publisher = {{BioMed Central (BMC)}}, series = {{Journal of Diabetes and Metabolic Disorders}}, title = {{Cystatin C as an adjunct to HbA1c may prove useful in predicting the development of diabetic complications in children and adolescents with type 1 diabetes}}, url = {{http://dx.doi.org/10.1007/s40200-024-01419-1}}, doi = {{10.1007/s40200-024-01419-1}}, volume = {{23}}, year = {{2024}}, }